keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant treatment

keyword
https://www.readbyqxmd.com/read/28092723/pertuzumab-and-breast-cancer-another-piece-in-the-anti-her2-puzzle
#1
Dr Lorenzo Gerratana, Dr Marta Bonotto, Dr Claudia Bozza, Dr Elena Ongaro, Dr Valentina Fanotto, Dr Giacomo Pelizzari, Prof Fabio Puglisi
The mechanism of action of pertuzumab, a recombinant anti-HER2 humanized monoclonal antibody, is complementary to trastuzumab's. On June 8, 2012, the Food and Drug Administration approved the combination of pertuzumab with trastuzumab and docetaxel as first-line treatment of HER2-positive metastatic breast cancer. Furthermore, pertuzumab is the first drug to be approved in the neoadjuvant setting using a pathological complete response as an endpoint. Areas covered: The review provides insights into the main mechanisms of action of pertuzumab...
January 16, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28091565/-18-f-flt-and-18-f-fdg-pet-ct-in-predicting-response-to-chemoradiotherapy-in-nasopharyngeal-carcinoma-preliminary-results
#2
Shi Qi, Yang Zhongyi, Zhang Yingjian, Hu Chaosu
The purpose of this study was to explore the feasibility of (18)F-Fluorothymidine ((18)F-FLT) and (18)F-Fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) in predicting treatment response of nasopharyngeal carcinoma (NPC). Patients with NPC of Stage II-IVB were prospectively enrolled, receiving 2 cycles of neoadjuvant chemotherapy (NACT), followed by concurrent chemoradiotherapy. Each patient underwent pretreatment and post-NACT FLT PET/CT and FDG PET/CT. Standard uptake values (SUV) and tumor volume were measured...
January 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28089283/myc-amplification-as-a-predictive-factor-of-complete-pathologic-response-to-docetaxel-based-neoadjuvant-chemotherapy-for-breast-cancer
#3
Cynthia Brito Lins Pereira, Mariana Ferreira Leal, Eliana Saul Furquim Werneck Abdelhay, Sâmia Demachki, Paulo Pimentel Assumpção, Mirian Carvalho de Souza, Caroline Aquino Moreira-Nunes, Adriana Michiko da Silva Tanaka, Marília Cardoso Smith, Rommel Rodríguez Burbano
BACKGROUND: Neoadjuvant chemotherapy is a standard treatment for stage II and III breast cancer. The identification of biomarkers that may help in the prediction of response to neoadjuvant therapies is necessary for a more precise definition of the best drug or drug combination to induce a better response. MATERIAL AND METHODS: We assessed the role of Ki67, hormone receptors expression, HER2, MYC genes and their protein status, and KRAS codon 12 mutations as predictor factors of pathologic response to anthracycline-cyclophosphamide (AC) followed by taxane docetaxel (T) neoadjuvant chemotherapy (AC+T regimen) in 51 patients with invasive ductal breast cancer...
December 24, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28087643/tumor-brca1-reversion-mutation-arising-during-neoadjuvant-platinum-based-chemotherapy-in-triple-negative-breast-cancer-is-associated-with-therapy-resistance
#4
Anosheh Afghahi, Kirsten M Timms, Shaveta Vinayak, Kristin C Jensen, Allison W Kurian, Robert W Carlson, Pei-Jen Chang, Elizabeth A Schackmann, Anne-Renee Hartman, James M Ford, Melinda L Telli
BACKGROUND: In germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers, restoration of tumor BRCA1/2 function by a secondary mutation is recognized as a mechanism of resistance to platinum and PARP inhibitors, primarily in ovarian cancer. We evaluated this mechanism of resistance in newly diagnosed BRCA1/2-mutant breast cancer patients with poor response to neoadjuvant platinum-based therapy. METHODS: PrECOG 0105 was a phase II neoadjuvant study of gemcitabine, carboplatin and iniparib in patients with stage I-IIIA triple-negative or BRCA1/2 mutation-associated breast cancer (n=80)...
January 13, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28087600/sunitinib-stimulates-expression-of-vegfc-by-tumor-cells-and-promotes-lymphangiogenesis-in-clear-cell-renal-cell-carcinomas
#5
Maeva Dufies, Sandy Giuliano, Damien Ambrosetti, Audrey Claren, Papa Diogop Ndiaye, Michalis Mastri, Walid Moghrabi, Lindsay S Cooley, Marc Ettaiche, Emmanuel Chamorey, Julien Parola, Valerie Vial, Marilena Lupu-Plesu, Jean-Christophe Bernhard, Alain Ravaud, Delphine Borchiellini, Jean Marc Ferrero, Andreas Bikfalvi, John M L Ebos, Khalid S A Khabar, Renaud Grepin, Gilles Pagès
Sunitinib is an antiangiogenic therapy given as a first-line treatment for renal cell carcinoma (RCC). While treatment improves progression-free survival, most patients relapse. We hypothesized that patient relapse can stem from the development of a lymphatic network driven by the production of the main growth factor for lymphatic endothelial cells, vascular endothelial growth factor C (VEGFC). In this study, we found that sunitinib can stimulate VEGFC gene transcription and increase VEGFC mRNA half-life. Additionally, sunitinib activated p38 MAP kinase, which resulted in the upregulation/activity of HuR and inactivation of tristetraprolin, two AU-rich-element binding proteins...
January 13, 2017: Cancer Research
https://www.readbyqxmd.com/read/28087389/evaluation-of-local-oncologic-safety-in-nipple-areola-complex-sparing-mastectomy-after-primary-chemotherapy-a-propensity-score-matched-study
#6
Roberto Agresti, Marco Sandri, Massimiliano Gennaro, Giulia Bianchi, Ilaria Maugeri, Mario Rampa, Giuseppe Capri, Maria Luisa Carcangiu, Giovanna Trecate, Egidio Riggio, Laura Lozza, Filippo de Braud
BACKGROUND: Nipple-areola complex-sparing mastectomy (NSM), extending the concept of skin-sparing mastectomy, allows for the provision of a better cosmetic result. Large operable T2-T3 breast cancer might theoretically appear suitable for this surgical option as an alternative to conventional mastectomy or breast-conserving surgery, when a good response to primary chemotherapy has been achieved. PATIENTS AND METHODS: From January 2009 to May 2013, 422 patients with invasive breast cancer were progressively accrued to NSM...
December 24, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28079398/feasibility-evaluation-of-diffusion-weighted-imaging-using-an-integrated-mri-radiotherapy-system-for-response-assessment-to-neoadjuvant-therapy-in-rectal-cancer
#7
Narek Shaverdian, Yingli Yang, Peng Hu, Steven Hart, Ke Sheng, James Lamb, Minsong Cao, Nzhde Agazaryan, David Thomas, Michael Steinberg, Daniel A Low, Percy Lee
OBJECTIVES: To evaluate the feasibility of on-board DWI with an integrated low-field MRI-radiotherapy system to assess responses to neoadjuvant chemoradiation (NAC) in rectal cancer. METHODS: A spin echo-based planar imaging diffusion sequence on a 0.35 T MRI-radiotherapy system was acquired over the course of NAC. The apparent diffusion coefficients (ADC) from the tumor region of interest (ROIs) were calculated. A functional diffusion map (fDM) was created showing a pixel-wise ADC analysis of the ROI over the course of treatment...
January 12, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28078854/changes-of-expression-of-estrogen-and-progestrone-receptors-human-epithelial-growth-factor-receptor-2-and-ki-67-after-neoadjuvant-chemotherapy-in-the-treatment-of-breast-cancer
#8
M L Li, Y Dong, S L Luan, Z H Zhao, F L Ning
Recent studies suggest that the development and prognosis of breast cancer is in close correlation to molecular subtype of breast cancer. Neoadjuvant chemotherapy has been extensively applied in the treatment of local breast cancer in advanced stage. In order to verify the correlation between expression changes of estrogen receptor, progestrone receptor, human epithelial growth factor receptor 2 and Ki-67 after neoadjuvant chemotherapy and neoadjuvant chemotherapy, we studied 120 patients with stage IIAIIIC breast cancer who underwent neoadjuvant chemotherapy in Binzhou Medical University Hospital, Shandong, China from February 2011 to February 2015...
October 2016: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/28078357/intralesional-treatment-of-metastatic-melanoma-a-review-of-therapeutic-options
#9
REVIEW
Benjamin Weide, Dario Neri, Giuliano Elia
Intralesional therapy of melanoma patients with locally advanced metastatic disease is attracting increasing interest, not least due to its ability to lead to both direct tumor cell killing and the stimulation of both a local and a systemic immune response. An obvious pre-requisite for this type of approach is the presence of accessible metastases that are amenable to direct injection with the therapeutic agent of interest. Patients who present with these characteristics belong to stages IIIB/C or IV of the disease...
January 11, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28078135/investigating-the-prognostic-value-of-koc-k-homology-domain-containing-protein-overexpressed-in-cancer-overexpression-after-curative-intent-resection-of-pancreatic-ductal-adenocarcinoma
#10
Benny Johnson, Maged Khalil, Joseph Blansfield, Fan Lin, Shaobo Zhu, H Lester Kirchner, Alva B Weir
BACKGROUND: Pancreatic adenocarcinoma (PDAC) is now the third leading cause of cancer mortality in the United States. More than 80% of patients present with distant metastasis precluding surgical eligibility. Even among patients with localized disease deemed eligible for surgical resection, the median survival is only 22.8 months due to high recurrence rates. Identification of a biomarker correlated with patient specific prognosis upon initial diagnosis can serve as a way to individualize treatment options...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28078125/changing-paradigm-in-pancreatic-cancer-from-adjuvant-to-neoadjuvant-chemoradiation
#11
Justin D Anderson, Wen Wan, Brian J Kaplan, Jennifer Myers, Emma C Fields
BACKGROUND: Historically, management of pancreatic cancer has been determined based on whether the tumor was amenable to resection and all patients deemed resectable received curative intent surgery followed by adjuvant therapy with chemotherapy (CT) ± RT. However, patients who undergo resection with microscopic (R1) positive margins have inferior rates of survival. The purpose of this study is to identify patients who have undergone pancreatectomy for pancreatic cancer, determine the surgical margins, types of adjuvant therapies given and patterns of failure...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28078118/less-than-12-lymph-nodes-in-the-surgical-specimen-after-neoadjuvant-chemo-radiotherapy-an-indicator-of-tumor-regression-in-locally-advanced-rectal-cancer
#12
Jaiprakash Gurawalia, Kapil Dev, Sandeep P Nayak, Vishnu Kurpad, Arun Pandey
BACKGROUND: The number of lymph node retrieved in the surgical specimen is important for tumor staging and has paramount impact on prognosis in colorectal cancer and imitates the adequacy of lymph node surgical clearance. The paucity of lymph node yields in patients undergoing resection after preoperative chemo radiotherapy (CRT) in rectal cancer has seen. Lower total number of lymph nodes in the total mesoractal excision (TME) specimen after CRT, could a marker of better tumor response...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28078108/egfr-family-and-cmet-expression-profiles-and-prognostic-significance-in-esophagogastric-adenocarcinoma
#13
Ellie Chan, Ahmad Alkhasawneh, Lizette Vila Duckworth, Tabish Aijaz, Tania Zuluaga Toro, Xiaomin Lu, Steven J Hughes, Amy Collinsworth, Thomas J George
BACKGROUND: Targeted therapy with anti-human epidermal growth factor receptor-2 (HER2) monoclonal antibody in patients with HER2 overexpressed esophagogastric adenocarcinoma (EGA) improves survival; however, the effect is transient due to the development of resistance. Some studies suggest that cMet overexpression provides cross talk for epidermal growth factor receptor (EGFR) and HER2 inhibition. We sought to characterize the expression profile of the EGFR family and cMet receptors in untreated, resected EGA...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28074265/pharmacokinetic-and-exposure-response-analyses-of-pertuzumab-in-combination-with-trastuzumab-and-docetaxel-during-neoadjuvant-treatment-of-her2-%C3%A2-early-breast-cancer
#14
Angelica L Quartino, Hanbin Li, Jin Y Jin, D Russell Wada, Mark C Benyunes, Virginia McNally, Lucia Viganò, Ihsan Nijem, Bert L Lum, Amit Garg
PURPOSE: The NeoSphere trial evaluated pertuzumab in the neoadjuvant setting [early breast cancer (EBC)] with pathological complete response (pCR) as the primary efficacy end point. This analysis of pertuzumab aimed to (1) compare its pharmacokinetics (PK) in patients with EBC versus advanced cancers, (2) to further evaluate PK drug-drug interactions (DDIs) when given in combination with trastuzumab, and (3) to assess the relationship between exposure and efficacy to assess the clinical dosing regimen in the EBC patients...
January 10, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28073896/patient-specific-circulating-tumor-dna-detection-during-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer
#15
Francesca Riva, Francois-Clement Bidard, Alexandre Houy, Adrien Saliou, Jordan Madic, Aurore Rampanou, Caroline Hego, Maud Milder, Paul Cottu, Marie-Paule Sablin, Anne Vincent-Salomon, Olivier Lantz, Marc-Henri Stern, Charlotte Proudhon, Jean-Yves Pierga
BACKGROUND: In nonmetastatic triple-negative breast cancer (TNBC) patients, we investigated whether circulating tumor DNA (ctDNA) detection can reflect the tumor response to neoadjuvant chemotherapy (NCT) and detect minimal residual disease after surgery. METHODS: Ten milliliters of plasma were collected at 4 time points: before NCT; after 1 cycle; before surgery; after surgery. Customized droplet digital PCR (ddPCR) assays were used to track tumor protein p53 (TP53) mutations previously characterized in tumor tissue by massively parallel sequencing...
January 10, 2017: Clinical Chemistry
https://www.readbyqxmd.com/read/28073374/successful-multimodal-treatment-of-intraoral-salivary-duct-carcinoma-in-a-patient-with-multiple-lymph-node-metastases-a-case-report
#16
Shuichi Imaue, Kei Tomihara, Takeru Hamashima, Gakuto Tomizawa, Kuninori Nomura, Masakiyo Sasahara, Makoto Noguchi
BACKGROUND: Salivary duct carcinoma (SDC) is a high-grade salivary gland malignancy that is associated with an aggressive clinical behavior and poor prognosis. Herein, we report on a long surviving case of SDC of the minor salivary gland with multiple lymph node metastases (LNMs). CASE PRESENTATION: An 83-year-old woman presented with a history of lymphadenopathy in the right side of the neck and recent onset and rapid growth of a mass in the right buccal region...
January 10, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28072456/systemic-inflammatory-markers-and-outcome-in-patients-with-locally-advanced-adenocarcinoma-of-the-oesophagus-and-gastro-oesophageal-junction
#17
V P Jagadesham, S M Lagarde, A Immanuel, S M Griffin
BACKGROUND: Raised levels of systemic inflammatory markers are associated with poor survival in patients with cancer. The aim of this study was to assess the prognostic value of markers of systemic inflammation in patients with adenocarcinoma of the oesophagus or gastro-oesophageal junction. METHODS: Data from a consecutive series of patients undergoing transthoracic oesophagectomy following neoadjuvant therapy at a single centre were analysed. Fibrinogen, albumin, C-reactive protein, leucocyte differential and platelet counts were measured before surgery...
January 10, 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28071613/clinical-and-pathologic-response-following-taxane-based-neoadjuvant-chemotherapy-in-locally-advanced-breast-cancer-patients-in-a-tertiary-care-centre-in-india
#18
Masillamany Sivasanker, S C Sistla, S Ali Manwar, S Vivekanandam
BACKGROUND: Neoadjuvant chemotherapy has become the standard recommendation in the management of patients with locally advanced breast cancer. At present anthracycline based regimen such as CAF (cyclophosphamide, adriamycin and 5-FU) is widely used in clinical practice. The introduction of taxanes has revolutionized this field because of superior results. AIMS AND OBJECTIVES: This study is designed to compare the efficacy of paclitaxel plus doxorubicin regimen and CAF (cyclophosphamide, doxorubicin and 5-fluorouracil) regimen as neoadjuvant treatment of locally advanced breast cancer and to compare their toxicity profiles and also to correlate the hormonal receptor status in predicting response to the NACT...
April 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28070651/inferior-vena-cava-involvement-in-children-with-wilms-tumor
#19
Abeer Al Diab, Nader Hirmas, Abdellatif Almousa, Ramiz Abu-Hijlih, Fatinah Aljlouni, Iyad Sultan, Khalil Ghandour
OBJECTIVES: Retrospective review of children with WT thrombus involving the IVC. METHODS: We reviewed the charts of 123 patients with WT diagnosed between January 2006 and December 2015. Patients with caval tumor thrombus were identified, demographic data, radiological images, extent of thrombus, chemo- and radiotherapy, surgical approach, pathology reports and outcomes were analyzed. RESULTS: IVC involvement was identified in 11 patients (9%)...
January 9, 2017: Pediatric Surgery International
https://www.readbyqxmd.com/read/28070166/biochemical-recurrence-prediction-in-high-risk-prostate-cancer-patients-following-robot-assisted-radical-prostatectomy
#20
Noriya Yamaguchi, Tetsuya Yumioka, Hideto Iwamoto, Toshihiko Masago, Shuichi Morizane, Masashi Honda, Takehiro Sejima, Atsushi Takenaka
BACKGROUND: High-risk prostate cancer treatment has been controversial. Some high-risk prostate cancer patients fail to respond to radical prostatectomy only. Thus, we aimed to investigate the predictive factors for biochemical recurrence (BCR) and identify patients who could achieve sufficient therapeutic effect by radical prostatectomy only. METHODS: Of 264 medical records reviewed, 141 low-intermediate-risk and 100 high-risk prostate cancer patients, excluding those who had received neoadjuvant hormone therapy, were analyzed...
December 2016: Yonago Acta Medica
keyword
keyword
50051
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"